Ketamine Encourages Nerve Remodeling

The commonly abused hallucinogen shows promise in extinguishing fear in rats, pointing to possible benefits for patients with post-traumatic stress disorder.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Ketamine bottles, Wikimedia, USGOV-DOJKetamine, a commonly used drug for sedation and general anesthesia and an abused hallucinogen, strengthens neuronal connections in the brain that help rats overcome oppressive fear, according to a presentation at this week’s Neuroscience 2012 conference in New Orleans, organized by the Society for Neuroscience (SfN). The study could have implications for the use of ketamine to treat patients with post-traumatic stress disorder (PTSD), who are often crippled by violent memories.

Current therapies for PTSD, including behavioral therapy and repeated exposure to stimuli representative of the original trauma, are largely unsuccessful at permanently ridding patients of their fear. “There is an urgent need to develop new drugs that improve current therapies,” study author Neil Fournier of Yale University School of Medicine said in a press release. “To extinguish fear, brain circuits must be remodeled and new nerve connections made, particularly in the brain’s medial prefrontal cortex. It now appears that ketamine spurs these kinds of changes.”

After conditioning rats to fear a particular tone, the researchers gave the animals ketamine or saline, then retrained them not to fear the tone. The next day, the rats that had been treated with ketamine were more likely to recall ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies